Alessia Mennitto

Novara, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 76 publications

International multicenter experience of prognostic factors and treatment outcomes of metastatic non-clear cell renal cell carcinoma.

International multicenter experience of prognostic factors and treatment outcomes of metastatic non-clear cell renal cell carcinoma.

Journal: Tumori
Published: May 04, 2026

Effectiveness and safety of avelumab maintenance in patients aged ≥75 years with advanced urothelial cancer: a sub-analysis of the meet-URO 25 (MALVA) study.

Effectiveness and safety of avelumab maintenance in patients aged ≥75 years with advanced urothelial cancer: a sub-analysis of the meet-URO 25 (MALVA) study.

Journal: Frontiers in immunology
Published: February 26, 2026

Patterns of first-line treatment selection in metastatic renal cell carcinoma: a real-world analysis from the Meet-URO 33-REGAL study.

Patterns of first-line treatment selection in metastatic renal cell carcinoma: a real-world analysis from the Meet-URO 33-REGAL study.

Journal: Therapeutic advances in medical oncology
Published: January 26, 2026

Enfortumab vedotin in ECOG-PS 2 advanced urothelial carcinoma patients: a real-world study from the ARON-2EV project.

Enfortumab vedotin in ECOG-PS 2 advanced urothelial carcinoma patients: a real-world study from the ARON-2EV project.

Journal: BMC cancer
Published: January 19, 2026

Concomitant medications and survival outcomes in patients receiving avelumab maintenance for advanced urothelial carcinoma: sub analysis of Meet-URO 25 study.

Concomitant medications and survival outcomes in patients receiving avelumab maintenance for advanced urothelial carcinoma: sub analysis of Meet-URO 25 study.

Journal: Clinical genitourinary cancer
Published: January 14, 2026

Long-Term Oncological Outcomes in Metastatic Prostate Cancer Patients Who Are Able to Maintain/Recover Ongoing Anticancer Therapy After SARS-CoV-2 Infection-Results of the MEET-URO 22 Study.

Long-Term Oncological Outcomes in Metastatic Prostate Cancer Patients Who Are Able to Maintain/Recover Ongoing Anticancer Therapy After SARS-CoV-2 Infection-Results of the MEET-URO 22 Study.

Journal: Cancers
Published: October 26, 2025

Effectiveness of ICI-ICI versus ICI-TKI combinations in patients with IMDC intermediate- and poor-risk metastatic renal cell carcinoma: a sub-analysis of the MEET-URO 33 study.

Effectiveness of ICI-ICI versus ICI-TKI combinations in patients with IMDC intermediate- and poor-risk metastatic renal cell carcinoma: a sub-analysis of the MEET-URO 33 study.

Journal: Cancer immunology, immunotherapy : CII
Published: October 24, 2025

Site and number of metastases predict outcomes in avelumab maintenance for advanced UC: results from meet-URO 25.

Site and number of metastases predict outcomes in avelumab maintenance for advanced UC: results from meet-URO 25.

Journal: Cancer immunology, immunotherapy : CII
Published: October 14, 2025

Real-life Use of Cabozantinib in Front-line therapy for Metastatic Renal Cell Carcinoma: The CabFRONT Study (Meet-URO 24).

Real-life Use of Cabozantinib in Front-line therapy for Metastatic Renal Cell Carcinoma: The CabFRONT Study (Meet-URO 24).

Journal: European urology open science
Published: September 28, 2025

Prognostic value of systemic inflammatory markers in avelumab maintenance for advanced urothelial carcinoma: the multicentric SAILOR analysis.

Prognostic value of systemic inflammatory markers in avelumab maintenance for advanced urothelial carcinoma: the multicentric SAILOR analysis.

Journal: Scientific reports
Published: July 21, 2025

Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?

Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?

Journal: Frontiers in immunology
Published: July 16, 2025

Real-world effectiveness of Avelumab maintenance in advanced urothelial carcinoma: results from the Italian multicenter MALVA study (Meet-URO 25).

Real-world effectiveness of Avelumab maintenance in advanced urothelial carcinoma: results from the Italian multicenter MALVA study (Meet-URO 25).

Journal: The oncologist
Published: June 06, 2025
Showing 1-12 of 76

Last Updated: 09/26/2026